Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.